Salarius Pharma rises on U.S. patent for potential cancer therapy
05/01/2023 15:08
** Shares of cancer drug developer Salarius Pharmaceuticals
Inc SLRX.O up 22.2% at $2.09
** Co says it has been granted U.S. patent for its molecular
glue degraders, which can be used to develop therapies for
patients with cancer
** Patent valid through September 2037
** Patent includes co's potential cancer drug SP-3204
** SLRX shares fell 87.7% last year
(Reporting by Mariam E Sunny)
((Mariam.ESunny@thomsonreuters.com;))